Stocks · News reference
8-K filing — Protalix BioTherapeutics, Inc. (PLX)
Filed: 2026-08-12 AccNo: 0001104659-26-094433 Size: 394 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Protalix (PLX) Q2 2026 Earnings Call Transcript
Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which